Dendritic cell-based immunotherapy
TLDR
What has been learned thus far about human DC biology from clinical studies are discussed, and how current approaches to apply DC vaccines in the clinic could be improved to enhance anti-tumor immunity are discussed.Abstract:
Immunotherapy using dendritic cell (DC)-based vaccination is an approved approach for harnessing the potential of a patient's own immune system to eliminate tumor cells in metastatic hormone-refractory cancer. Overall, although many DC vaccines have been tested in the clinic and proven to be immunogenic, and in some cases associated with clinical outcome, there remains no consensus on how to manufacture DC vaccines. In this review we will discuss what has been learned thus far about human DC biology from clinical studies, and how current approaches to apply DC vaccines in the clinic could be improved to enhance anti-tumor immunity.read more
Citations
More filters
Journal ArticleDOI
Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy.
TL;DR: The biological functions of immune cells within TME and their roles in cancer immunotherapy are reviewed, and the perspectives of the basic studies for improving the effectiveness of the clinical use are discussed.
Journal ArticleDOI
Therapeutic Targeting of the Tumor Microenvironment
TL;DR: A comprehensive analysis of the current therapies targeting the tumor microenvironment (TME) is provided in this paper, combining a discussion of the underlying basic biology with clinical evaluation of different therapeutic approaches, and highlighting the challenges and future perspectives.
Journal ArticleDOI
Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape
TL;DR: It is argued that in various contexts next-generation DC vaccines are ready to meet some challenges currently confronting ICIs, thereby raising the need to integrate DC vaccines in future combinatorial immunotherapy regimens.
Journal ArticleDOI
Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
TL;DR: The role of the different immune landscapes in CRC and their relationships with defined CRC genetic subtypes are discussed and in which ways CRC cells develop mechanisms to resist ICI are considered.
Journal ArticleDOI
Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source
TL;DR: This review summarized the current knowledge on the application of EVs as DDS from the perspective of different cell origin and weighted the advantages and bottlenecks of EV-based DDS.
References
More filters
Journal ArticleDOI
Antibodies targeting Clec9A promote strong humoral immunity without adjuvant in mice and non-human primates.
Jessica Li,Jessica Li,Fatma Ahmet,Lucy C. Sullivan,Andrew G. Brooks,Stephen J. Kent,Robert De Rose,Andres M Salazar,Caetano Reis e Sousa,Ken Shortman,Ken Shortman,Ken Shortman,Mireille H. Lahoud,Mireille H. Lahoud,William R. Heath,Irina Caminschi,Irina Caminschi +16 more
TL;DR: It is shown that induction of humoral immunity to CLEC9A‐targeted antigens is extremely effective in nonhuman primates, in an adjuvant‐free setting.
Book ChapterDOI
Apoptotic cells at the crossroads of tolerance and immunity.
TL;DR: How apoptotic cells manipulate immunity through interactions with dendritic cells is discussed, which involves Preferential ligation of specific receptors on professional antigen-presenting cells (dendritic Cells) to induce potentially tolerogenic signals.
Journal ArticleDOI
Genetic engineering of T cells for adoptive immunotherapy
Angel Varela-Rohena,Carmine Carpenito,Elena E. Perez,Max W. Richardson,Richard V. Parry,Michael C. Milone,John Scholler,Xueli Hao,Angela M. Mexas,Richard G. Carroll,Carl H. June,James L. Riley +11 more
TL;DR: This article focuses on strategies to dissect the signals controlling T cell proliferation; render CD4 T cells resistant to HIV-1 infection; and redirect CD8 T cell antigen specificity.
Journal ArticleDOI
A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T cell immunity in vivo
Austin R. Pantel,Cheolho Cheong,Durga Bhavani Dandamudi,Elina Shrestha,Saurabh Mehandru,Luke Brane,Darren Ruane,Angela Teixeira,Leonia Bozzacco,Ralph M. Steinman,Paula M Longhi +10 more
TL;DR: Analysis of the adjuvant capacity of glucopyranosyl lipid A in mice indicates that a synthetic and clinically feasible TLR4 agonist rapidly stimulates full maturation of DCs in vivo, allowing for adaptive immunity to develop many weeks to months later.
Journal ArticleDOI
Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells
TL;DR: Lentiviral vectors expressing the reporter gene GFP or the melanoma-associated antigen tyrosinase were used to transduce three different kinds of human APC, and Substituting the CAG promoter for PGK in lentiviral constructs enhanced transgene expression in DC and EBV-B cells, amplifying T cell recognition.
Related Papers (5)
Dendritic cells and the control of immunity
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
F. Stephen Hodi,Steven J. O'Day,David F. McDermott,R. W. Weber,Jeffrey A. Sosman,John B. A. G. Haanen,Rene Gonzalez,Caroline Robert,Dirk Schadendorf,Jessica C. Hassel,Wallace Akerley,Alfons J.M. van den Eertwegh,Jose Lutzky,Paul Lorigan,Julia Vaubel,Gerald P. Linette,David W. Hogg,Christian H. Ottensmeier,Céleste Lebbé,Christian Peschel,Ian Quirt,Joseph I. Clark,Jedd D. Wolchok,Jeffrey S. Weber,Jason Tian,Michael Yellin,Geoffrey M. Nichol,Axel Hoos,Walter J. Urba +28 more